Display Settings:

Items per page
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 6

1.
Fig. 3.

Fig. 3. From: Treatment of medulloblastoma with a modified measles virus.

Replication of MV-GFP in D283med (A) and UW426 (B) cells is demonstrated by the titers obtained daily for 5 days at an MOI of 0.1, 1, and 10. Titration was done on Vero cells in a 96-well plate using the 50% end-dilution method.

Adam W. Studebaker, et al. Neuro Oncol. 2010 October;12(10):1034-1042.
2.
Fig. 1.

Fig. 1. From: Treatment of medulloblastoma with a modified measles virus.

CD46 expression in medulloblastoma cell lines and tissue samples. (A) CD46 is highly expressed on the cell surface of medulloblastoma cells. Cells were stained with an anti-CD46 PE antibody (gray histogram) or an isotype control (black histogram) and analyzed by flow cytometry. (B) Immunohistochemical detection of CD46 in a medulloblastoma patient sample.

Adam W. Studebaker, et al. Neuro Oncol. 2010 October;12(10):1034-1042.
3.
Fig. 5.

Fig. 5. From: Treatment of medulloblastoma with a modified measles virus.

Histological examination (H&E stain) of SCID brain following administration of MV-GFP (A and B) or UV-inactivated MV-GFP (C and D). There is no evidence of tumor in the MV-GFP treated animal (A, ×20 and B, ×100). The remnant of the needle tract (arrow; B, ×100) with associated gliosis and hemosiderin-laden macrophages is seen in the MV-GFP-treated animal. In a mouse treated with UV-inactivated MV-GFP, there is significant tumor growth and mass effect (C, ×20) with tumor infiltration into the adjacent normal brain (D, ×400).

Adam W. Studebaker, et al. Neuro Oncol. 2010 October;12(10):1034-1042.
4.
Fig. 2.

Fig. 2. From: Treatment of medulloblastoma with a modified measles virus.

Cytopathic effect of MV-GFP. (A) The viability of D283 and UW426 human medulloblastoma cells following administration of MV-GFP at an MOI of 0.1, 1, and 10.0. Less than 20% of the cells were viable at 72 h postinfection at an MOI of 1, and <1% of the cells were viable at 120 h postinfection at an MOI of 10. (B) The medulloblastoma cell line D283med was infected with MV-GFP at an MOI of 0.1, 1, and 10, and showed GFP expression and syncytium formation 48 and 72 h postinfection. The experiment was performed in quadruplicate, and a second independent experiment displayed similar results.

Adam W. Studebaker, et al. Neuro Oncol. 2010 October;12(10):1034-1042.
5.
Fig. 4.

Fig. 4. From: Treatment of medulloblastoma with a modified measles virus.

Antitumor effect of MV-GFP. D283 medulloblastomas were established in the right frontal lobe of female SCID mice (10–11 mice/group). Seven days after tumor implantation, the mice received a total of 107 pfu of MV-GFP or the same dose of UV inactivated MV-GFP. Mice treated with MV-GFP had significantly longer survival times than mice that received UV-inactivated MV-GFP (P < 0.01). A second independent experiment also demonstrated significant (P < 0.001) survival times of mice treated with MV-GFP when compared with mice that received UV-inactivated MV-GFP (data not shown).

Adam W. Studebaker, et al. Neuro Oncol. 2010 October;12(10):1034-1042.
6.
Fig. 6.

Fig. 6. From: Treatment of medulloblastoma with a modified measles virus.

In vivo evaluation of antitumor activity of MV-GFP. (A) Bioluminescence images and corresponding (B) signal intensities obtained from mice containing D283Luc tumors. Animals were implanted with D283Luc cells 7 days prior to treatment. MV-GFP treatment was administered on days 0, 2, 4, 6, and 8. The bioluminescence signal was significantly decreased in MV-GFP–treated animals whereas the signal significantly increased in the untreated animals. (A) The MV-GFP–treated animal on the left exhibits complete tumor abolition, whereas the animal on the right exhibits significant regression (day 15), followed by an increase in tumor burden (day 29). Tumor regression was also observed in a third animal in the MV-GFP–treated group (animal not shown). Two additional untreated animals exhibited significant tumor increase (animals not shown).

Adam W. Studebaker, et al. Neuro Oncol. 2010 October;12(10):1034-1042.

Display Settings:

Items per page

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk